Sarepta Therapeutics (NASDAQ:SRPT) Issues Earnings Results

Sarepta Therapeutics (NASDAQ:SRPT) announced its quarterly earnings data on Wednesday. The biotechnology company reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.38 by $0.12, Zacks reports. Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT traded down $0.09 during midday trading on Wednesday, hitting $106.86. The company’s stock had a trading volume of 1,068,904 shares, compared to its average volume of 813,754. The firm’s 50 day moving average is $116.73 and its 200-day moving average is $123.01. The firm has a market cap of $10.21 billion, a P/E ratio of 85.49 and a beta of 0.75. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics has a fifty-two week low of $101.15 and a fifty-two week high of $173.25.

Analysts Set New Price Targets

SRPT has been the topic of a number of recent analyst reports. Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. Guggenheim boosted their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. HC Wainwright restated a “sell” rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 13th. Piper Sandler cut their price objective on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Sarepta Therapeutics in a research report on Tuesday, February 11th. They set a “hold” rating and a $136.00 target price on the stock. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $176.77.

Insiders Place Their Bets

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. This represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.